返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® NeuroTech Attends 17th OCIN

[2017-11-24] 

Shanghai, China – From October 26 to October 29, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the 17th Oriental Conference of Interventional Neuroradiology ("OCIN 2017") and displayed APOLLO Intracranial Stent System ("APOLLO"), WILLIS® Intracranial Stent Graft System ("WILLIS®"), and other core products. As the one of the most influential congresses in the field of neurointervention in China, the OCIN 2017 attracted nearly 2,000 domestic and overseas experts from the neurointervention field to exchange ideas on new theories, new technologies, and new materials.
 
In the OCIN, live cases are the always the highlighted session. On October 30, Professor Ziliang Wang of Henan Provincial People’s Hospital used APOLLO to treat long-segment chronic total occlusion, and Professor Chuhan Jiang of Beijing Tiantan Hospital of Capital Medical University used WILLIS® to treat left ophthalmic artery aneurysms. The two cases both achieved successful results and demonstrated the excellent performance of MicroPort® NeuroTech products, which attracted wide attention from experts in attendance.
 
In the session of "new product and new technology", Professor Chun Fang of Tongji Hospital of Tongji University delivered a speech of "the Application of WILLIS®". He said, Blood Blister-like Aneurysms ("BBA"), originated from internal carotid supraclinoid anterior wall non-furcation area, is easy to rupture and cause bleeding during the operation. WILLIS® Endovascular Repair Technique is the feasible method to treat internal carotid artery BBA as it can effectively reduce the risk of rebleeding and reoccurrence. Professor Chun Fang shared his own clinical experience in treating 13 BBA patients with WILLIS® from 2013 to 2015, and the excellent clinical performance of WILLIS® won high recognition from experts in attendance.
On October 29, MicroPort® NeuroTech held a book-signing event of "Endovascular Reconstruction with WILLIS® for Cerebro-vascular Diseases" in which it invited the author Professor Minghua Li of Shanghai Sixth People’s Hospital to sign and hand out the books for free. The book vividly illustrates the application of WILLIS® in treating extracranial internal carotid artery and vertebral artery. It contains 111 cases and over 500 pictures, explaining the material selection, operation procedure and treatment effect of different cases to provide reference to neurointerventional physicians.
 
During the congress, MicroPort® NeuroTech organized a workshop and invited Professor Minghua Li, Professor Bing Leng of Huashan Hospital of Fudan University, and Professor Chun Fang of Tongji Hospital of Tongji University as guest speakers. More than 50 professionals from the neurointervention field were attracted to share and discuss clinical experience in WILLIS®, and the reviews and explanations from the guest speakers further enhanced their understandings in the indications and operation of WILLIS®.
 
In OCIN 2017, many experts visited MicroPort® NeuroTech booth and exchanged ideas with MicroPort® NeuroTech R&D staff regarding possible difficulties in clinical trials, as well as new development and new trend in the field of neurovascular intervention. The experts said they are looking forward to the market launch of Tubridge™ Vascular Reconstruction Device ("Tubridge™"), an innovative device in-house developed by MicroPort® NeuroTech in the treatment of cerebral aneurysms, to benefit more domestic patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:FOXTROT™ NC PTCA Balloon Catheter Gains Regulatory Approval in Argentina
[Next]:WALTZ™ Gains Regulatory Approval in Brazil